topic contract-manufacturing-biopharmaceutical-production 
Roots Analysis
AUGUST 16, 2023
The success of COVID-19 vaccines paved the path for mRNA-based drug products. Safety, efficacy and rapid production of mRNA drives the interest in this domain. Concluding Remarks Currently, dozens of preclinical and clinical reports demonstrating the efficacy of these platforms have been published in the last two years alone.
Roots Analysis
AUGUST 29, 2023
In this context, it is worth highlighting those 14 biopharmaceutical products ( including cell therapies, gene therapies, monoclonal antibodies and recombinant proteins ) were approved in the US alone, in 2021. As a result, biopharmaceutical contract manufacturing has picked up pace in the recent years.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Roots Analysis
AUGUST 29, 2023
In this context, it is worth highlighting those 14 biopharmaceutical products ( including cell therapies, gene therapies, monoclonal antibodies and recombinant proteins ) were approved in the US alone, in 2021. As a result, biopharmaceutical contract manufacturing has picked up pace in the recent years.
Pharmaceutical Technology
FEBRUARY 8, 2023
Genenta Science and AGC Biologics have signed a development and manufacturing service agreement (MSA). Under the deal, AGC Biologics will be responsible for manufacturing the cell therapy lentivirus-based product for the ongoing clinical programmes of Genenta Science.
Pharmaceutical Technology
AUGUST 17, 2022
Biopharmaceutical contract development and manufacturing organisation (CDMO) AGC Biologics has entered a strategic collaboration with RoosterBio to expedite the manufacturing of cell and exosome therapies. It will also have the potential to scale to Phase III clinical development and commercial manufacturing.
European Pharmaceutical Review
OCTOBER 5, 2023
Ahead of her presentation on the future of biomanufacturing at CPHI Barcelona, Sheila Ann Mikhail, the co-founder and former CEO of AskBio, engages in a conversation about gene therapy, artificial intelligence, and the importance of being a well-informed innovator when selecting a manufacturing partner.
Pharmaceutical Technology
JUNE 2, 2023
As we look to find new and better ways to treat ophthalmic diseases, we want to get it right and ensure that our product candidates can be scaled up appropriately for each development stage and, ultimately, for commercialisation. The company is a global contract development and manufacturing organisation (CDMO) for biopharmaceuticals.
Expert insights. Personalized for you.
52 
Let's personalize your content